BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 22, 2025
Home » Topics » Science

Science
Science RSS Feed RSS

Microbiome illustration

Bringing back butyrate is antigen-agnostic approach to food allergies

Aug. 23, 2022
By Anette Breindl
Treating mice with butyrate, a short-chain fatty acid that is normally produced by beneficial gut microbes, prevented anaphylactic shock in allergic mice when they were exposed to peanuts after treatment. It also reduced inflammation in animals with colitis.
Read More
Brain and DNA

New genes and mutations linked to autism

Aug. 22, 2022
By Mar de Miguel
Two large-scale studies provide new data on genes, inherited variations, and de novo mutations associated with autism spectrum disorder. Some of them are also associated with other neurological conditions, like developmental delay, or schizophrenia.
Read More
Amyloid plaque on nerve cell

Fusion protein reduces amyloid with less inflammation

Aug. 19, 2022
By Mar de Miguel
A fusion protein removed beta-amyloid plaque without producing the neurotoxic inflammation associated with other treatments, such as aducanumab immunotherapy. It is based on the alphaA Beta-Gas6 fusion protein developed in a mouse model of Alzheimer's disease by a team of researchers at The Korea Advanced Institute of Science and Technology in South Korea.
Read More

From p53 loss to cancer, a series of unfortunate events

Aug. 18, 2022
By Mar de Miguel
The development of cancer after p53 inactivation is determined by a series of genomic changes that occur in four steps. The loss of heterozygosity of TP53 (the gene encoding p53 in humans, named Trp53 in mice) is followed by an accumulation of deletions, genome doubling, and the emergence of gains and amplifications. In a study published in the August 17, 2022, issue of Nature, researchers have further observed that these four phases of genomic evolution are associated with specific histological stages before and after the malignant condition developed.
Read More
RNA

Antisense oligonucleotides targeting LINE-1 RNA could be used to treat premature aging

Aug. 17, 2022
By Nuala Moran
Scientists have discovered an RNA-based mechanism that is involved in core hallmarks of a number of accelerated aging conditions and shown that therapies targeting this RNA reverses some of these hallmarks in human cells and extend life spans in mouse models.
Read More
Marco Caffio working with Gii technology

Scottish researchers team up to develop liver transplant test

Aug. 12, 2022
By Catherine Longworth
Integrated Graphene Ltd. is partnering with a team of scientists at the University of Edinburgh to develop a point-of-care biomedical test for liver transplants. The Sensibile project team is working to develop a prototype electrochemical biosensor that can detect biliary complications’ biomarkers in donor livers. Sterling, Scotland-based Integrated Graphene’s 3D graphene foam electrode will help to assess the viability of the biliary compartment, and the quality of the donor liver prior to transplantation.
Read More
Neuron

New screening platform reveals neurodegeneration drug targets in microglia

Aug. 12, 2022
By Nuala Moran
As the resident innate immune cells of the brain, microglia are emerging as key drivers of neurological diseases, but as yet there is no systematic way of exploring their potential as drug targets.
Read More
CAR T cell attacking cancer cells

New method developed to produce generic CAR T cells at scale

Aug. 12, 2022
By Mar de Miguel
A new method has been devised to produce generic chimeric antigen receptor (CAR) T cells at scale by directing induced pluripotent stem cells to differentiate into mature T cells in vitro. The generic T cells can then be engineered to express a range of different chimeric antigen receptors.
Read More
Cancer cells under magnifying glass

Metastasizing melanoma cells hijack gene involved in development of the nervous system

Aug. 11, 2022
By Nuala Moran
Scientists at the Institute of Cancer Research in London have discovered that melanoma cells spread by harnessing a gene normally involved in the development of the nervous system.
Read More
HIV infected cell

AIDS 2022: Scientists report progress in understanding how to eliminate latent HIV reservoirs

Aug. 10, 2022
By Mar de Miguel
Researchers around the world are making advances in understanding how HIV becomes latent and seeking out vulnerabilities that could provide routes to targeting reservoirs and eliminating them.
Read More
Previous 1 2 … 46 47 48 49 50 51 52 53 54 … 188 189 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing